There has certainly not been much of a media roll out about the data. Maybe that's because the new CEO doesn't start for another month but who knows really. The fact the "n" number of non memantine patients certainly plays a roll (14 patients through the 30 day follow on I think) but as Dr Alkon says its "black and white" in the data that memantine ruins the bryostatin response. I'm surprised they aren't trying to get the story out better, explain how they got Dr Perry to jump on board, status of the Fragile X trial, any comments from the FDA, etc and do some interviews with actual questions because at some point we need the share price higher whether for partnership or whatever type funding it will take place long term. Obviously it isn't hard to get this stock to run so at some point they'll announce the institution for the trial and parameters/timelines and such and the stock will likely respond. I mean if you announce Stanford (just a guess because of their bryostatin familiarity, could be anyone) is conducting a trial for us it will certainly add to our credibility. Of course getting some type of partnership would be our biggest market cap boost I would think. No matter what the company says the bloggers of the world will bash, but if I were the company I wouldn't let it bother me if I knew I had the goods. JMHO
News 
Market Data 
Discover 
